Patentability of parthenogenic stem cells questioned
Another reference has been made to the Court of Justice of the European Union (CJEU) for a preliminary ruling on the patentability of stem cells, under Directive 98/44/ED (the Biotechnology Directive). The case is called International Stem Cell Corporation (ISCC) v Comptroller General of Patents. The question referred concerns whether stem cells obtained from parthenogenically stimulated human ova are excluded from patentability as ‘human embryos’.
The reference follows an earlier ruling by the CJEU in its Brüstle decision (C-34/10) that stem cells obtained from human embryos directly, or indirectly, are unpatentable and its application in the German Supreme Court.
However, the technology used by ISCC uses parthogenetic activation of oocytes and so does not involve the destruction of a fertilised ovum capable of developing into a human being. For this reason, it is seen as a more ethical alternative to the technology at issue in Brüstle…
If you are registered and logged in to the site, click on the link below to read the rest of the Taylor Wessing briefing. If not, please register or sign in with your details below.
News from Taylor Wessing
News from The Lawyer
Briefings from Taylor Wessing
A ratchet is a structure whereby the eventual equity allocations between the shareholders depend on future performance of the company or the rate of return achieved by the venture capital firm.
The venture capital investors in an investment round normally require that certain actions cannot be taken without the consent of the holders of a majority of their class or series of shares.
Analysis from The Lawyer
The city-state is working hard to become a global wealth management hub, and law firms are gearing up for a prosperous new world
Financial disputes are starting to dominate the English courts as the long-awaited fallout from the downturn finally comes to town